A trend for oligoclonal leukemia in STI571-treated mice.

Genomic DNA was prepared from peripheral blood granulocytes from either STI571-treated (right, lanes 6-9) or STI571-untreated (left, lanes 1-5) mice, digested with the restriction enzyme BglII, and then analyzed by Southern blot by means of a neomycin probe. There is only a single BglII site within the proviral sequence recognized by the neomycin probe, with the second BglII site located in adjacent genomic DNA. Therefore, each leukemic clone will have a unique BglII fragment recognized by the probe.13 As controls, an oligoclonal lymphoid tumor cell line established from a mouse with the Bcr/Abl–induced ALL-like illness (lane 10) and BM cells from a syngeneic healthy mouse (lane 11) are shown at right.